In 2 recent studies, VAF was an independent prognostic factor in predicting response to hypomethylating agents in patients with TP53 mutant MDS,27 and in the context of AML, the impact of TP53 VAF may be dependent on treatment intensity.10 The gene discussed is TP53; the disease is acute myeloid leukemia.